Vol 17, No 1 (2020)
Review paper
Get Citation

Aripiprazole: monotherapy?

Agata Szulc
DOI: 10.5603/PSYCH.2020.0005
·
Psychiatria 2020;17(1):29-35.

paid access

Vol 17, No 1 (2020)
Prace poglądowe - nadesłane

Abstract

Polypharmacy, meaning combining two or more antipsychotic agents, is frequently used not only in Poland, but across the world. It is estimated, that even 2/3 of patients receive polypharmacy. It may be justified in the acute phase of illness and/or in the treatment resistant patients, or during the switching period from one drug to another. However, it should not be treated as a routine practice because of the increased risk of the adverse events. The analysis of the long-term adverse events of polypharmacy is essential, since those events may increase over the time. Amongst them the weight increase, glucose intolerance, hyperlipidemia, extrapyramidal symptoms, hyperprolactinemia, OTc prolongation and sedation are observed. Aripiprazole is one of the atypical or II generation antipsychotics known for several years. Many clinical trials and everyday practice confirm its clinical efficacy in schizophrenia and bipolar disorder. It is frequently used in the combination with the other antipsychotics. This paper reviews data about aripiprazole application in monotherapy, which should become a routine practice in the mental diseases treatment.

Abstract

Polypharmacy, meaning combining two or more antipsychotic agents, is frequently used not only in Poland, but across the world. It is estimated, that even 2/3 of patients receive polypharmacy. It may be justified in the acute phase of illness and/or in the treatment resistant patients, or during the switching period from one drug to another. However, it should not be treated as a routine practice because of the increased risk of the adverse events. The analysis of the long-term adverse events of polypharmacy is essential, since those events may increase over the time. Amongst them the weight increase, glucose intolerance, hyperlipidemia, extrapyramidal symptoms, hyperprolactinemia, OTc prolongation and sedation are observed. Aripiprazole is one of the atypical or II generation antipsychotics known for several years. Many clinical trials and everyday practice confirm its clinical efficacy in schizophrenia and bipolar disorder. It is frequently used in the combination with the other antipsychotics. This paper reviews data about aripiprazole application in monotherapy, which should become a routine practice in the mental diseases treatment.
Get Citation

Keywords

aripiprazole, monotherapy, schizophrenia, bipolar disorder

About this article
Title

Aripiprazole: monotherapy?

Journal

Psychiatria (Psychiatry)

Issue

Vol 17, No 1 (2020)

Article type

Review paper

Pages

29-35

DOI

10.5603/PSYCH.2020.0005

Bibliographic record

Psychiatria 2020;17(1):29-35.

Keywords

aripiprazole
monotherapy
schizophrenia
bipolar disorder

Authors

Agata Szulc

References (33)
  1. Szulc A, Więdlocha M, Marcinowicz P. Arypiprazol. Via Medica, Gdańsk 2018.
  2. Szulc A, Więdlocha M. Arypiprazol – częściowy agonizm, pelna skuteczność. Psychiatria. 2017; 14(1): 1–6.
  3. de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015; 29(9): 773–799.
  4. FDA U. Inventor drug approval package, Abilify (aripiprazole) tablets. http: //www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails2002..
  5. Charakterystyka produktu leczniczego Abilify. http: //leki.urpl.gov.pl/files/Abilify_ tabl_15mg .pdf..
  6. Szulc A, Samochowiec J, Gałecki P, et al. Recommendations for the treatment of schizophrenia with negative symptoms. Standards of pharmacotherapy by the Polish Psychiatric Association (Polskie Towarzystwo Psychiatryczne), part 1. Psychiatria Polska. 2019; 53(3): 497–524.
  7. Sparshatt A, Taylor D, Patel MX, et al. A systematic review of aripiprazole--dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010; 71(11): 1447–1456.
  8. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019; 394(10202): 939–951.
  9. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896): 951–962.
  10. Ribeiro EL, de Mendonça Lima T, Vieira ME, et al. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. Eur J Clin Pharmacol. 2018; 74(10): 1215–1233.
  11. Keck PE, Marcus R, Tourkodimitris S, et al. Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003; 160(9): 1651–1658.
  12. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole Study Group. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006; 20(4): 536–546.
  13. Suppes T, Eudicone J, McQuade R, et al. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord. 2008; 107(1-3): 145–154.
  14. Brown R, Taylor MJ, Geddes J. Aripiprazole alone or in combination for acute mania. Cochrane Database Syst Rev. 2013(12): CD005000.
  15. Muneer A. The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review. Cureus. 2016; 8(4): e562.
  16. Li DJ, Tseng PT, Stubbs B, et al. Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2017; 79(Pt B): 289–301.
  17. Takeshima M. Treating mixed mania/hypomania: a review and synthesis of the evidence. CNS Spectr. 2017; 22(2): 177–185.
  18. Betzler F, Stöver LA, Sterzer P, et al. Mixed states in bipolar disorder - changes in DSM-5 and current treatment recommendations. Int J Psychiatry Clin Pract. 2017; 21(4): 244–258.
  19. Chakrabarty T, Keramatian K, Yatham LN. Treatment of mixed features in bipolar disorder: an updated view. Curr Psychiatry Rep. 2020; 22(3): 15.
  20. Zareifopoulos N, Panayiotakopoulos G. Treatment options for acute agitation in psychiatric patients: theoretical and empirical evidence. Cureus. 2019; 11(11): e6152.
  21. Jarema M. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Wydanie 2. Wyd. Via Medica, Gdańsk. : 2015.
  22. Poyurovsky M, Bergman J, Pashinian A, et al. Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia. Int Clin Psychopharmacol. 2014; 29(5): 296–298.
  23. Citrome L, Eramo A, Francois C, et al. Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatr Dis Treat. 2015; 11: 3095–3104.
  24. Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015; 11: 2635–2647.
  25. Englisch S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(6): 1386–1392.
  26. Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D. 2015; 15(1): 45–62.
  27. Weiss C, Weiller E, Baker RA, et al. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies. Int Clin Psychopharmacol. 2018; 33(5): 255–260.
  28. Galling B, Roldán A, Rietschel L, et al. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opin Drug Saf. 2016; 15(5): 591–612.
  29. Hatta K, Sugiyama N, Ito H. Switching and augmentation strategies for antipsychotic medications in acute-phase schizophrenia: latest evidence and place in therapy. Ther Adv Psychopharmacol. 2018; 8(6): 173–183.
  30. Ijaz S, Bolea B, Davies S, et al. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC Psychiatry. 2018; 18(1): 275.
  31. Lin SK. Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion? Int J Neuropsychopharmacol. 2019 [Epub ahead of print].
  32. Wróbel K, Szulc A. Schizofrenia z przeważającymi objawami negatywnymi 2019 – badanie epidemiologiczno-społeczne. Psychiatria. 2019; 16(3): 107–113.
  33. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003; 6(4): 325–337.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl